M&A

News

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Incyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.

News

Lilly gets back in infectious disease, via three M&A deals

Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8bn.

News

GBL joins CVC in €10.7bn takeover bid for Recordati

A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.

R&D

Why UCB bet a billion dollars on cell therapy for epilepsy

UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.

News

GHO, CBC merge to create largest healthcare investment firm

Two top healthcare investors – UK-based GHO and CBC Group of Singapore – have announced a merger to create a massive player in the category.

News

Roche buys AI-powered diagnostics player PathAI

Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy it for $1.05bn.

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Lilly gets back in infectious disease, via three M&A deals

GBL joins CVC in €10.7bn takeover bid for Recordati

Why UCB bet a billion dollars on cell therapy for epilepsy

GHO, CBC merge to create largest healthcare investment firm

Roche buys AI-powered diagnostics player PathAI

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks